Browse recruiting and upcoming clinical trials for congenital adrenal hyperplasia.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this list Hide ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
26 trials + 17 related Sex All Female (includes ALL) Male (includes ALL) All sexes only
Age All ages Pediatric (under 18) Adult (18+)
Clear Who can join AI Children 3 months to <4 years with classic congenital adrenal hyperplasia (21‑hydroxylase deficiency).
What is being studied AI Tests safety, tolerability, and drug PK/PD of crinecerfont in young children.
Study type Treatment (drug) · Phase 2
Who can join AI Male or female at birth, age 1 to <18 years, with medically confirmed classic congenital adrenal hyperplasia due to 21‑hydroxylase deficiency.
What is being studied AI Tests atumelnant (oral) for safety, efficacy, and pharmacokinetics/pharmacodynamics in pediatric CAH.
Study type Treatment (drug) · Phase 2/3
Countries Argentina, Australia, Belgium +9
Who can join AI Adults (18–74 years) with classic congenital adrenal hyperplasia (CAH) due to 21‑hydroxylase deficiency (21‑OHD).
What is being studied AI Tests once-daily oral atumelnant versus placebo for hormone control and safety in classic CAH.
Study type Treatment (drug) · Phase 3
Countries Argentina, Australia, Austria +12
Who can join AI People aged 16–74 with congenital adrenal hyperplasia (including classic CAH) who completed a Crinetics parent atumelnant CAH study.
What is being studied AI Long-term safety, tolerability, and efficacy of atumelnant (CRN04894) in CAH.
Study type Treatment (drug) · Phase 2
Countries Argentina, Brazil, Germany +3
Who can join AI Adults 18 to 70 with 21‑hydroxylase deficiency congenital adrenal hyperplasia (CAH).
What is being studied AI Tests safety, tolerability, and how Lu AG13909 behaves and affects hormones in CAH.
Study type Treatment (drug) · Phase 1/2
Countries Denmark, France, Georgia +6
Who can join AI Adults (age >18) with congenital adrenal hyperplasia due to 21‑hydroxylase deficiency.
What is being studied AI Compares once-daily dual-release hydrocortisone with conventional glucocorticoids in adults with CAH.
Study type Treatment (drug) · Phase 4
Who can join AI People with congenital adrenal hyperplasia (CAH) who previously received asedebart in an earlier clinical trial.
What is being studied AI Long-term safety, tolerability, blood drug levels, and hormone effects of asedebart.
Study type Treatment (drug) · Phase 2
Who can join AI People with classic congenital adrenal hyperplasia (CAH).
What is being studied AI Tests whether different doses of NBIP-01435 reduce elevated androstenedione (A4) levels.
Study type Treatment (drug) · Phase 2
Who can join AI People aged 15–20 with chronic endocrine conditions (e.g., congenital adrenal hyperplasia, Turner or Klinefelter syndrome, Addison's disease).
What is being studied AI Tests whether the YESS! game plus toolkit changes self-management scores and clinic drop-out.
Study type Treatment (other)
Countries Belgium, Netherlands, Spain +1
Who can join AI Mid- to late pubertal girls (ages 10–17) with hyperandrogenism or PCOS who meet the study's puberty and health requirements.
What is being studied AI Whether spironolactone changes progesterone's suppression of waking LH pulse frequency.
Who can join AI Pubertal girls ages 10–17 in mid-to-late puberty, with or without hyperandrogenism.
What is being studied AI Whether short-term oral progesterone acutely changes waking versus sleep LH pulse frequency in pubertal girls.
Who can join AI Medically healthy adults ages 18–55 (healthy volunteers).
What is being studied AI Tests safety, pharmacokinetics, and effects on adrenal hormones, including a food effect.
Who can join AI People who had neonatal salt loss from an endocrine cause other than 21-hydroxylase-deficient CAH, with onset in the first 60 days of life.
What is being studied AI Collects clinical, genetic, and treatment data on neonatal salt loss from non-21-hydroxylase endocrine causes
Who can join AI Adults with congenital adrenal hyperplasia (CAH): men 18–65 years and pre‑menopausal women 18–55 years.
What is being studied AI Collects reproductive, hormonal, metabolic, immune, imaging, and molecular data from people with CAH.
Who can join AI Women aged 18 years or older with genetically confirmed classic 21-hydroxylase deficiency (CAH).
What is being studied AI Collects pregnancy history, parental plans, pregnancy outcomes, and hormone-replacement adjustments.
Who can join AI Women aged ≥18 who received antenatal dexamethasone for a pregnancy at risk of congenital adrenal hyperplasia.
What is being studied AI Collects obstetric, endocrine and metabolic data in women given antenatal dexamethasone.
Who can join AI Women with hyperandrogenism, metabolic disease, or sex-hormone adverse reactions.
What is being studied AI Collects hormones, metabolic and metabolome data to study androgens' links to women's metabolic risk.
Who can join AI Adults (18+) with complex rare genetic syndromes listed in the study, e.g., Prader‑Willi, Turner, Noonan, Rett and others.
What is being studied AI Collects and analyzes adult medical records to describe health problems, labs, symptoms, and medication use.
Who can join AI People with congenital adrenal hyperplasia (CAH), familial male-limited precocious puberty (FMPP), other androgen excess, and relatives of affected patients.
What is being studied AI Collects medical, hormonal, genetic, imaging, and cognitive data on people with androgen excess.
Who can join AI Children and adolescents with congenital adrenal hyperplasia (21‑hydroxylase deficiency) treated for adrenal insufficiency and hyperandrogenism.
What is being studied AI Compares paired salivary and serum steroid measurements across the day using LC-MS/MS.
Who can join AI Adolescents and young people (age ≥16) with congenital adrenal hyperplasia, plus their caregivers and pediatric CAH clinical providers.
What is being studied AI Tests feasibility and acceptability of a structured healthcare transition program for adolescents and young adults with CAH.
Who can join AI Female patients aged 16 to 45 with hyperandrogenism (including those with confirmed causes).
What is being studied AI Tests machine learning combined with metabolomics to distinguish causes of hyperandrogenism.
Who can join AI People with classic congenital adrenal hyperplasia (21‑hydroxylase deficiency).
What is being studied AI Measures adult patients' regret, quality of life, sexual function, and treatment history using questionnaires.
Who can join AI Men aged 18 or older with congenital adrenal hyperplasia due to 21-hydroxylase deficiency and a known CYP21A2 genotype.
What is being studied AI Collects clinical and lab data to build an electronic registry and describe gonadal function and prevalence.
Who can join AI People of any age with a clinical or molecular diagnosis of one or more of the listed rare diseases.
What is being studied AI Collects and organizes clinical data to create a single institutional registry for many rare diseases.
Who can join AI Adults (≥18) with genetically confirmed 21‑hydroxylase deficiency CAH who have switched from conventional glucocorticoids to modified‑release hydrocortisone.
What is being studied AI Collects long-term clinical and lab outcomes in adults with CAH on modified‑release hydrocortisone.
Trials that may include congenital adrenal hyperplasia (17) ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AI Female adolescents with suspected or confirmed PCOS/PMOS who are overweight or obese.
What is being studied AI Tests whether adding lean beef to a healthy meal plan changes blood sugar control and diet quality.
Study type Treatment (diet)
Who can join AI Women with polycystic ovary syndrome (PCOS).
What is being studied AI Tests magnesium and levocarnitine supplements' effects on blood sugar, lipids, and hirsutism in PCOS.
Study type Treatment (diet)
Who can join AI Adults with mild autonomous cortisol secretion (MACS) and an adrenal adenoma confirmed by imaging.
What is being studied AI Tests osilodrostat (Isturisa) effects on metabolic, body composition, bone, vascular, and adrenal measures.
Study type Treatment (drug) · Phase 4
Who can join AI Adults (18+) diagnosed with Mild Autonomous Cortisol Secretion (MACS) or Autonomous Cortisol Secretion (ACS).
What is being studied AI Tests metyrapone versus placebo for safety and biological effects in people with MACS.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (18+) with mild autonomous cortisol secretion (MACS) or autonomous cortisol secretion (ACS).
What is being studied AI Tests safety/tolerability of 1 mg osilodrostat and effects on urine steroid profile and circadian cortisol.
Study type Treatment (drug) · Phase 2
Who can join AI Women aged 18–40 with polycystic ovary syndrome (PCOS) and insulin resistance / hyperandrogenism with BMI 25–40.
What is being studied AI Compares acupuncture, metformin (each with lifestyle) versus lifestyle alone for insulin resistance in PCOS.
Study type Treatment (drug) · Phase 2
Who can join AI People aged 18–75 with primary aldosteronism due to adrenal hyperplasia and coexisting chronic kidney disease who are planning unilateral adrenalectomy.
What is being studied AI Tests whether short-term postoperative hydrocortisone versus standard care affects eGFR change at 12 months.
Study type Treatment (drug) · Phase 4
Who can join AI Adults 18–70 with active Cushing's disease caused by increased ACTH secretion.
What is being studied AI Tests adding cabergoline to osilodrostat versus osilodrostat alone for cortisol control and safety.
Study type Treatment (drug) · Phase 4
Who can join AI People with primary aldosteronism.
What is being studied AI Tests whether [18F]CETO PET/CT can identify subtypes of primary aldosteronism.
Who can join AI Women with Polycystic Ovarian Syndrome (PCOS) or self-reported PCOS symptoms.
What is being studied AI Whether Milamend supplement affects quality of life, hormones, menstrual cycles, and metabolic markers.
Who can join AI Pubertal girls (females age 10–17) with hyperandrogenism, including those with PCOS.
What is being studied AI Tests whether spironolactone changes sleep-time LH pulse frequency versus placebo in pubertal girls with hyperandrogenism.
Who can join AI Adults 18–45 with type 1 diabetes and/or polycystic ovary syndrome (PCOS), plus matched male and non‑hyperandrogenic control groups.
What is being studied AI Collects metabolic, hormonal, genetic, epigenetic, tissue and body-composition data to study hyperandrogenism.
Who can join AI Women diagnosed with PCOS or related features such as hyperinsulinism, hyperandrogenism, or metabolic syndrome.
What is being studied AI Measures vascular, myocardial and endothelial markers during OGTT and after six months of treatment.
Who can join AI Children (up to 18 years) born to women diagnosed with polycystic ovary syndrome (PCOS).
What is being studied AI Collects health data and biological samples to study effects of prenatal PCOS exposure on offspring.
Who can join AI Adolescent girls with PCOS, metabolic steatotic liver disease (MASLD), pediatric obesity, hyperandrogenism, or insulin resistance.
What is being studied AI Compares liver fat by elastography and an extended blood biomarker and genetic panel.
Who can join AI Women with polycystic ovary syndrome (PCOS) or insulin resistance.
What is being studied AI Compares blood preptin levels and their relationship with insulin resistance in women with and without PCOS.
Who can join AI People of any age who have a congenital portosystemic shunt (CPSS).
What is being studied AI Collects clinical and biological data to study the natural history and outcomes of CPSS.
Countries Australia, Belgium, Canada +13